Objective To approach clinic efficacy and safety of long-acting nifedipine combined magnesium sulfate in the treatment of severe pregnancy-induced hypertension syndrome before birth. Methods The 60 patients with pregnancy-in-duced hypertension syndrome from January 2012 to January 2013 were divided into the observation group and the control group randomly,30 cases in each group. The patients in the control group were treated with routine therapy ,while those in the observa-tion group were treated with long-acting nifedipine combined magnesium sulfate. The clinic effect and safety in the two groups were evaluated. Results The total effective rate in the observation group (96.67%,29/30) was higher than that in the control group(76.67%,23/30),and the difference between the two groups was statistically significant(χ2=3.605 769,P<0.05). The mean arterial pressure and urine protein quantitation in 24 h of the patients in the observation group[ (112.06±4.17)mm Hg(1 mm Hg=0.133 kPa) and(1.85±0.97)g respectively] after treatment were superior to those in the control group[(123.36±4.53)mm Hg and (2.13±0.88)g respectively] with statistically significant difference(t=12.37,3.45,P<0.05). Conclusion The clinic effect of long-acting nifedipine combined magnesium sulfate is obvious ,and it is worthy of promotion and application.%目的：探讨硫酸镁联合长效硝苯地平产前治疗重度妊娠高血压综合征的临床疗效和安全性。方法将2012年1月至2013年1月收治的重度妊娠高血压综合征患者60例随机分为观察组和对照组各30例。对照组给予常规治疗，观察组同时给予硫酸镁联合长效硝苯地平治疗，评估两组临床疗效及安全性。结果观察组总有效率（96.67%，29/30）明显高于对照组（76.67%，23/30），差异有统计学意义（χ2=3.605769，P＜0.05）。治疗后观察组患者平均动脉压及24 h尿蛋白定量[分别为（112.06±4.17）mm Hg（1 mm Hg=0.133 kPa）、（1.85±0.97）g]明显低于对照组[分别为（123.36±4.53）mm Hg、（2.13±0.88）g]，差异有统计学意义（t=12.37、3.45，P＜0.05）。结论硫酸镁联合长效硝苯地平产前治疗重度妊娠高血压综合征临床效果显著，值得推广应用。
展开▼
